Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T cell leukemia: a risk of opportunistic infection after treatment with anti-CCR4 antibodies

MeSH terms

• Aged
• Aged, 80 and over
• Antibodies, Monoclonal, Humanized / adverse effects
• Antibodies, Monoclonal, Humanized / therapeutic use*
• Antibody-Dependent Cell Cytotoxicity
• Antineoplastic Combined Chemotherapy Protocols / administration & dosage
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Antiviral Agents / therapeutic use
• Combined Modality Therapy
• Cyclophosphamide / administration & dosage
• Cyclophosphamide / adverse effects
• Cytomegalovirus Infections / drug therapy
• Cytomegalovirus Infections / etiology*
• Doxorubicin / administration & dosage
• Doxorubicin / adverse effects
• Doxorubicin / analogs & derivatives
• Encephalitis, Viral / drug therapy
• Encephalitis, Viral / etiology
• Female
• Ganciclovir / therapeutic use
• Humans
• Immunosuppressive Agents / adverse effects
• Immunosuppressive Agents / therapeutic use*
• Leukemia-Lymphoma, Adult T-Cell / drug therapy
• Leukemia-Lymphoma, Adult T-Cell / therapy*
• Male
• Middle Aged
• Neoplasm Proteins / antagonists & inhibitors*
• Neoplasm Proteins / immunology
• Opportunistic Infections / drug therapy
• Opportunistic Infections / etiology*
• Prednisolone / administration & dosage
• Prednisolone / adverse effects
• Receptors, CCR4 / antagonists & inhibitors*
• Receptors, CCR4 / immunology
• Remission Induction
• Stevens-Johnson Syndrome / diagnosis
• Stevens-Johnson Syndrome / etiology
• Vincristine / administration & dosage
• Vincristine / adverse effects